Drug Manufacturers - General
Compare Stocks
5 / 10Stock Comparison
SRXH vs ALHC vs HIMS vs CVS vs TDOC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Equipment & Services
Medical - Healthcare Plans
Medical - Healthcare Information Services
SRXH vs ALHC vs HIMS vs CVS vs TDOC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - General | Medical - Healthcare Plans | Medical - Equipment & Services | Medical - Healthcare Plans | Medical - Healthcare Information Services |
| Market Cap | $1M | $3.73B | $6.63B | $111.40B | $1.26B |
| Revenue (TTM) | $119M | $4.26B | $2.35B | $407.90B | $2.51B |
| Net Income (TTM) | $-11M | $20M | $128M | $2.93B | $-171M |
| Gross Margin | 19.9% | 9.0% | 69.7% | 13.9% | 65.6% |
| Operating Margin | -4.9% | 0.8% | 4.6% | 1.5% | -7.6% |
| Forward P/E | — | 140.9x | 51.5x | 12.2x | — |
| Total Debt | $39M | $338M | $1.12B | $93.59B | $1.04B |
| Cash & Equiv. | $2M | $578M | $229M | $8.51B | $781M |
SRXH vs ALHC vs HIMS vs CVS vs TDOC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| SRx Health Solution… (SRXH) | 100 | 5.8 | -94.2% |
| Alignment Healthcar… (ALHC) | 100 | 103.0 | +3.0% |
| Hims & Hers Health,… (HIMS) | 100 | 77.5 | -22.5% |
| CVS Health Corporat… (CVS) | 100 | 130.9 | +30.9% |
| Teladoc Health, Inc. (TDOC) | 100 | 96.8 | -3.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SRXH vs ALHC vs HIMS vs CVS vs TDOC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SRXH plays a supporting role in this comparison — it may shine differently against other peers.
ALHC is the clearest fit if your priority is growth exposure.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
HIMS is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 161.9% 10Y total return vs ALHC's 5.4%
- 59.0% revenue growth vs TDOC's -1.5%
- 5.5% margin vs SRXH's -9.4%
- 6.0% ROA vs SRXH's -22.4%, ROIC 10.7% vs -18.1%
CVS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Lower volatility, beta 0.05, current ratio 0.84x
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Better valuation composite
Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs TDOC's -1.5% | |
| Value | Better valuation composite | |
| Quality / Margins | 5.5% margin vs SRXH's -9.4% | |
| Stability / Safety | Beta 0.05 vs HIMS's 2.40, lower leverage | |
| Dividends | 3.1% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +34.7% vs SRXH's -84.6% | |
| Efficiency (ROA) | 6.0% ROA vs SRXH's -22.4%, ROIC 10.7% vs -18.1% |
SRXH vs ALHC vs HIMS vs CVS vs TDOC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
SRXH vs ALHC vs HIMS vs CVS vs TDOC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HIMS leads in 2 of 6 categories
SRXH leads 0 • ALHC leads 0 • CVS leads 0 • TDOC leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 3429.5x SRXH's $119M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to SRXH's -9.4%. On growth, ALHC holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $119M | $4.3B | $2.3B | $407.9B | $2.5B |
| EBITDAEarnings before interest/tax | — | $66M | $164M | $10.5B | $42M |
| Net IncomeAfter-tax profit | — | $20M | $128M | $2.9B | -$171M |
| Free Cash FlowCash after capex | — | $237M | $73M | $7.4B | $251M |
| Gross MarginGross profit ÷ Revenue | +19.9% | +9.0% | +69.7% | +13.9% | +65.6% |
| Operating MarginEBIT ÷ Revenue | -4.9% | +0.8% | +4.6% | +1.5% | -7.6% |
| Net MarginNet income ÷ Revenue | -9.4% | +0.5% | +5.5% | +0.7% | -6.8% |
| FCF MarginFCF ÷ Revenue | +1.3% | +5.6% | +3.1% | +1.8% | +10.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +33.3% | +28.4% | +6.2% | -2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +2.1% | -27.3% | +63.1% | +32.1% |
Valuation Metrics
Evenly matched — SRXH and CVS each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 50.3x trailing earnings, HIMS trades at a 20% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than ALHC's 77.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1M | $3.7B | $6.6B | $111.4B | $1.3B |
| Enterprise ValueMkt cap + debt − cash | $29M | $3.5B | $7.5B | $196.5B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.17x | -4932.43x | 50.32x | 62.81x | -6.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 140.93x | 51.51x | 12.19x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 77.12x | 42.68x | 13.11x | 15.13x |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 0.94x | 2.82x | 0.28x | 0.50x |
| Price / BookPrice ÷ Book value/share | — | 20.16x | 12.25x | 1.47x | 0.89x |
| Price / FCFMarket cap ÷ FCF | 1.20x | 32.95x | 89.61x | 14.27x | 4.40x |
Profitability & Efficiency
HIMS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-12 for TDOC. TDOC carries lower financial leverage with a 0.75x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), ALHC scores 6/9 vs SRXH's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +11.5% | +23.7% | +3.9% | -12.4% |
| ROA (TTM)Return on assets | -22.4% | +1.8% | +6.0% | +1.1% | -5.9% |
| ROICReturn on invested capital | -18.1% | — | +10.7% | +5.0% | -11.5% |
| ROCEReturn on capital employed | -98.8% | +2.9% | +10.9% | +6.1% | -10.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 1.89x | 2.07x | 1.24x | 0.75x |
| Net DebtTotal debt minus cash | $37M | -$240M | $892M | $85.1B | $259M |
| Cash & Equiv.Liquid assets | $2M | $578M | $229M | $8.5B | $781M |
| Total DebtShort + long-term debt | $39M | $338M | $1.1B | $93.6B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | 1.27x | — | 2.11x | -8.76x |
Total Returns (Dividends Reinvested)
Evenly matched — ALHC and HIMS and CVS each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $461 for TDOC. Over the past 12 months, CVS leads with a +34.7% total return vs SRXH's -84.6%. The 3-year compound annual growth rate (CAGR) favors ALHC at 36.2% vs SRXH's -62.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -52.9% | -9.7% | -23.2% | +10.6% | -1.3% |
| 1-Year ReturnPast 12 months | -84.6% | +17.6% | -51.0% | +34.7% | +1.5% |
| 3-Year ReturnCumulative with dividends | -94.6% | +152.4% | +116.6% | +36.6% | -73.3% |
| 5-Year ReturnCumulative with dividends | -94.6% | -22.7% | +137.6% | +17.0% | -95.4% |
| 10-Year ReturnCumulative with dividends | -94.6% | +5.4% | +161.9% | +3.5% | -41.1% |
| CAGR (3Y)Annualised 3-year return | -62.3% | +36.2% | +29.4% | +11.0% | -35.6% |
Risk & Volatility
Evenly matched — SRXH and CVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRXH is the less volatile stock with a -0.32 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs SRXH's 9.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.32x | 0.75x | 2.40x | 0.05x | 1.91x |
| 52-Week HighHighest price in past year | $1.25 | $23.87 | $70.43 | $88.63 | $9.77 |
| 52-Week LowLowest price in past year | $0.08 | $11.63 | $13.74 | $58.35 | $4.40 |
| % of 52W HighCurrent price vs 52-week peak | +9.0% | +76.5% | +36.4% | +98.5% | +71.2% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 37.3 | 54.5 | 69.3 | 74.1 |
| Avg Volume (50D)Average daily shares traded | 22.0M | 3.6M | 34.9M | 7.4M | 5.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ALHC as "Buy", HIMS as "Hold", CVS as "Buy", TDOC as "Hold". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs 8.9% for TDOC (target: $8). CVS is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | — | $24.83 | $29.67 | $95.20 | $7.58 |
| # AnalystsCovering analysts | — | 16 | 19 | 41 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +3.1% | — |
| Dividend StreakConsecutive years of raises | — | — | — | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | $2.67 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% | 0.0% |
HIMS leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
SRXH vs ALHC vs HIMS vs CVS vs TDOC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SRXH or ALHC or HIMS or CVS or TDOC a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Alignment Healthcare, Inc. (ALHC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SRXH or ALHC or HIMS or CVS or TDOC?
On trailing P/E, Hims & Hers Health, Inc.
(HIMS) is the cheapest at 50. 3x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SRXH or ALHC or HIMS or CVS or TDOC?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -95. 4% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus SRXH's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SRXH or ALHC or HIMS or CVS or TDOC?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc.
(SRXH) is the lower-risk stock at -0. 32β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -844% more volatile than SRXH relative to the S&P 500. On balance sheet safety, Teladoc Health, Inc. (TDOC) carries a lower debt/equity ratio of 75% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SRXH or ALHC or HIMS or CVS or TDOC?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SRXH or ALHC or HIMS or CVS or TDOC?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus -9. 4% for SRx Health Solutions Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SRXH or ALHC or HIMS or CVS or TDOC more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 128. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.
08Which pays a better dividend — SRXH or ALHC or HIMS or CVS or TDOC?
In this comparison, CVS (3.
1% yield) pays a dividend. SRXH, ALHC, HIMS, TDOC do not pay a meaningful dividend and should not be held primarily for income.
09Is SRXH or ALHC or HIMS or CVS or TDOC better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SRXH and ALHC and HIMS and CVS and TDOC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SRXH is a small-cap high-growth stock; ALHC is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock; TDOC is a small-cap quality compounder stock. CVS pays a dividend while SRXH, ALHC, HIMS, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.